DISCUSSION: This study demonstrated that decreased plasma PDGFRβ levels are associated with BBB damage, Aβ plaques, tau tangles, neurodegeneration, and cognitive decline in AD, and modulate the relationship between plasma tau biomarkers and both longitudinal neurodegeneration and cognitive decline. This evidence concerns the gene MAPT and Alzheimer disease.